Skip to main content

2 Result(s)

within S Bursi Remove this filter

and

  1. Article

    Open Access

    A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer

    The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substitut...

    E Vasile, G Masi, L Fornaro, S Cupini, F Loupakis, S Bursi… in British Journal of Cancer (2009)

    Download PDF (156 KB) View Article

  2. No Access

    Article

    A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer

    The GONO-FOLFOXIRI regimen demonstrated higher activity and efficacy than FOLFIRI in metastatic colorectal cancer patients. The aim of this study was to determine the maximum tolerated dose of capecitabine, in...

    Lorenzo Fornaro, G. Masi, S. Bursi, F. Loupakis… in Cancer Chemotherapy and Pharmacology (2009)